Recent advancements in dermatology have highlighted the SIK2 psoriasis therapeutic target as a potential breakthrough for managing chronic inflammatory skin conditions. Psoriasis remains a significant clinical challenge characterized by immune dysregulation and keratinocyte hyperproliferation. A new study explores how salt-inducible kinase 2 (SIK2) interacts with C-X-C motif chemokine ligand 5 (CXCL5) to modulate interleukin-23 (IL-23) secretion in neutrophils.

Furthermore, researchers utilized an imiquimod (IMQ)-induced mouse model to observe these molecular interactions. They found that increasing SIK2 levels significantly reduced ear thickness and neutrophil infiltration. Consequently, the study demonstrated that SIK2 acts as a negative regulator of the inflammatory cascade in this model. Conversely, overexpressing CXCL5 reversed these protective benefits, suggesting that CXCL5 is a critical downstream effector.

Investigating the SIK2 Psoriasis Therapeutic Target

In addition to animal models, in vitro experiments on activated neutrophils corroborated these findings. Specifically, neutrophils transfected with SIK2 constructs showed reduced viability and lower levels of pro-inflammatory cytokines, including IL-17 and IL-23. Moreover, SIK2 appears to influence the phosphorylation of Yes-associated protein (p-YAP). This complex interplay underscores SIK2 as a pivotal modulator of the neutrophil-driven inflammatory response in psoriasis.

Additionally, the study examined the impact of SIK2 on matrix metallopeptidase 9 (MMP9) and other cytokines like TNF-α and IL-1β. Therefore, the results provide compelling evidence that SIK2 modulates the inflammatory milieu by regulating the CXCL5-IL-23 axis. Ultimately, targeting this pathway could lead to more precise treatments for patients suffering from moderate to severe psoriasis.

Frequently Asked Questions

How does SIK2 influence psoriasis progression?

According to the study, SIK2 acts as a critical modulator by reducing the secretion of IL-23 and CXCL5. This suppresses the inflammatory response and limits neutrophil infiltration into the skin.

What is the relationship between CXCL5 and IL-23 in this context?

The research suggests that CXCL5 facilitates the secretion of IL-23 in neutrophils. When SIK2 levels are increased, CXCL5 is inhibited, which consequently lowers IL-23 levels and alleviates psoriatic symptoms.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional consultation. Refer to the latest local and national guidelines for clinical practice.

References

Li Y et al. Exploring SIK2-CXCL5 interactions in neutrophils: A novel mechanism for modulating IL-23 and psoriasis progression. Immunol Cell Biol. 2026 Mar 23. doi: 10.1111/imcb.70105. PMID: 41867147.

Furuya H et al. IL-23 induces CLEC5A+ IL-17A+ neutrophils and elicit skin inflammation associated with psoriatic arthritis. J Autoimmun. 2024 Feb;143:103167.

Childs B et al. Updates in Psoriasis Treatments. J Clin Aesthet Dermatol. 2025;18(2):16-22.